(CRVO)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
| Dr. John J. Alam M.D. | Co-Founder, CEO, President & Director |
| Dr. Marinus Verwijs Ph.D. | Executive Vice President of Technical Operations |
| Dr. Mark A. De Rosch Ph.D. | Executive VP of Regulatory, Government Affairs & Program Management |
| Dr. Matthew Winton Ph.D. | Chief Commercial & Business Officer |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder & Director |
| Mr. William Robert Elder J.D. | CFO, General Counsel & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-03-19 | 8-K | crvo20260319_8k.htm |
| 2026-03-17 | 8-K | crvo20260317_8k.htm |
| 2026-03-13 | 10-K | crvo20251231_10k.htm |
| 2026-03-04 | 8-K | crvo20260304_8k.htm |
| 2026-01-08 | 8-K | crvo20260108_8k.htm |
| 2025-12-05 | 8-K | crvo20251205_8k.htm |
| 2025-11-10 | 8-K | crvo20251110_8k.htm |
| 2025-11-07 | 10-Q | crvo20250930_10q.htm |
| 2025-11-04 | 8-K | crvo20251104_8k.htm |
| 2025-10-29 | 8-K | crvo20251029c_8k.htm |
| Ms. Kelly Blackburn M.H.A. | Executive Vice President of Clinical Development |